March 16, 2011
By Medimaging International staff writers
For the first time, quantitative–not qualitative–data analysis has demonstrated that time-of-flight (TOF) positron emission tomography (PET) imaging scans can improve cancer detection. Research revealed that oncologic TOF fluorodeoxyglucose (FDG) PET scans yielded considerable improvements in lesion detection of lung and liver cancers over all contrasts and body mass indexes.
Traditional PET scans create images by detecting gamma rays produced by radioisotopes that are injected into the body. Although these conventional scans track where the gamma rays go, they do not gauge the time it takes for each gamma ray to reach the detector. TOF PET scans do take into account the travel time, which results in improved image signal-to-noise.
“[We] …aimed to objectively quantify the improvement in lesion detection that can be achieved with whole-body TOF FDG PET,” said Dr. Joel S. Karp, from the department of radiology, University of Pennsylvania (Philadelphia, USA), and one of the authors of the study, which was published in the March 2011 issue of the Journal of Nuclear Medicine. “In contrast with previously published studies that reported comparison of TOF and non-TOF PET using simulated data or measured data with physical phantoms, this study used whole-body patient data…”
To create a lesion-present-clinical-study while ensuring precise knowledge of the presence and location of each lesion, 10-mm spheric lesions were added to disease-free bed positions, yielding fused lesion-present studies. These studies appropriately corrected for the body’s attenuation so that the presence or absence of the lesions was similar to that of actual patient studies. TOF PET scans were performed, and researchers used a numeric observer–as opposed to a human observer–to identify quickly a large number of conditions. The TOF PET images were compared to traditional PET images (the same data reconstructed without TOF information) to determine improvement in lesion detection as a function of lesion location, scan time, contrast and body mass index.
Improved lesion detection was seen in the TOF PET scans, with the greatest gains achieved in the shortest-acquisition studies and in the subjects with a BMI of 30 or more. Also of interest–the greatest gain in performance was achieved at the lowest lesion contrast and the smallest gain in performance at the highest lesion contrast.
Nuclear medicine technologists and physicians may be able to take advantage of the gain achieved with TOF PET to reduce scanning time, therefore increasing patient comfort and minimizing patient motion. They may also be able to reduce the injected radiopharmaceutical dose, thereby reducing the exposure of patients and health professionals to radiation.